Clinical Trials in South Korea / NCT07415031
Recruiting
Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031 · tracked via the Priya Life Science South Korea tracker
Condition(s) studied
Solid Tumors
Investigational drug(s) / intervention(s)
Adagrasib →Pembrolizumab →Cetuximab →Pemetrexed →Docetaxel →Irinotecan →Leucovorin →Oxaliplatin →Fluorouracil →
Adagrasib: Specified dose on specified days
Pembrolizumab: Specified dose on specified days
Cetuximab: Specified dose on specified days
Pemetrexed: Specified dose on specified days
Docetaxel: Specified dose on specified days
Irinotecan: Specified dose on specified days
Leucovorin: Specified dose on specified days
Oxaliplatin: Specified dose on specified days
Fluorouracil: Specified dose on specified days
Study summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Eligibility
Inclusion Criteria:
* Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
* Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.
Exclusion Criteria:
* Participant is not eligible for study treatment per the parent study eligibility criteria.
* Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
* Participants not receiving clinical benefit from parent study drug as assessed by the investigator.
Other protocol defined inclusion/exclusion criteria applies.
Primary outcome measure(s)
- Number of Participants With Adverse Events (AEs) — Up to 90 days from last dose or study discontinuation
- Number of Participants With AEs Leading to Treatment Discontinuation — Up to 90 days from last dose or study discontinuation
- Number of Participants With Serious Adverse Events (SAEs) — Up to 90 days from last dose or study discontinuation
- Number of Participants With AEs Leading to Death — Up to 90 days from last dose or study discontinuation
Trial sites (102)
| Facility | City | Region | Status |
|---|---|---|---|
| Local Institution - 0005 | Phoenix | Arizona | Withdrawn |
| Southern California Permanente Medical Group | Bellflower | California | Recruiting |
| MemorialCare - Long Beach Medical Center | Long Beach | California | Recruiting |
| Local Institution - 0003 | Newark | Delaware | Withdrawn |
| Florida Cancer Specialists - North | St. Petersburg | Florida | Recruiting |
| Cancer Center of Kansas | Wichita | Kansas | Recruiting |
| Local Institution - 0092 | Boston | Massachusetts | Withdrawn |
| Dana Farber Cancer Center | Boston | Massachusetts | Recruiting |
| Mayo Clinic in Rochester, Minnesota | Rochester | Minnesota | Recruiting |
| Metro-Minnesota Community Oncology Research Consortium (MMCORC) | Saint Paul | Minnesota | Recruiting |
| Nebraska Cancer Specialists | Omaha | Nebraska | Recruiting |
| Oncology Associates Of Oregon, Pc | Eugene | Oregon | Recruiting |
| The West Clinic, PLLC dba West Cancer Center | Germantown | Tennessee | Recruiting |
| Texas Oncology-Bedford | Bedford | Texas | Recruiting |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | Recruiting |
| Texas Oncology - DFW | Grapevine | Texas | Recruiting |
| PeaceHealth St. Joseph Medical Center | Bellingham | Washington | Recruiting |
| Local Institution - 0093 | St Leonards | New South Wales | Withdrawn |
| AZ Maria Middelares | Ghent | Belgium | Recruiting |
| Local Institution - 0108 | São Paulo | Brazil | Not Yet Recruiting |
| Local Institution - 0111 | São Paulo | Brazil | Not Yet Recruiting |
| BC Cancer - Vancouver | Vancouver | British Columbia | Recruiting |
| Local Institution - 0037 | Beijing | Beijing Municipality | Withdrawn |
| Local Institution - 0045 | Xiamen | Fujian | Not Yet Recruiting |
| Local Institution - 0042 | Zhengzhou | Henan | Not Yet Recruiting |
| Local Institution - 0038 | Changsha | Hunan | Not Yet Recruiting |
| Local Institution - 0046 | Nanjing | Jiangsu | Not Yet Recruiting |
| Local Institution - 0048 | Nanchang | Jiangxi | Not Yet Recruiting |
| Local Institution - 0049 | Shenyang | Liaoning | Not Yet Recruiting |
| Local Institution - 0039 | Jinan | Shandong | Not Yet Recruiting |
| Local Institution - 0047 | Linyi | Shandong | Not Yet Recruiting |
| Local Institution - 0043 | Shanghai | Shanghai Municipality | Not Yet Recruiting |
| Local Institution - 0040 | Chengdu | Sichuan | Not Yet Recruiting |
| Local Institution - 0044 | Hangzhou | Zhejiang | Not Yet Recruiting |
| Local Institution - 0041 | Xi'an | China | Not Yet Recruiting |
| Local Institution - 0076 | Nice | Alpes-Maritimes | Not Yet Recruiting |
| Centre Antoine-Lacassagne | Nice | Alpes-Maritimes | Recruiting |
| Nouvel Hôpital Civil (NHC) | Strasbourg | Alsace | Recruiting |
| Local Institution - 0103 | Pessac | Aquitaine | Not Yet Recruiting |
| Chu Jean Minjoz | Besançon | Doubs | Recruiting |
+ 62 more sites — see the full list on the official registry below.
On this site
📄 Keytruda (pembrolizumab) drug profile →More Mirati Therapeutics Inc. trials in South Korea
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07415031 on ClinicalTrials.gov ↗ ← All trials in South Korea